The arbitration award significantly strengthens CASI's balance sheet and reduces the need for dilutive capital raises. Monitor the actual cash receipt and any updates on CID-103 pipeline development as the company now has extended runway.
Price Chart
Executive Summary
CASI Pharmaceuticals won a final arbitration award against Juventas, with the tribunal rejecting all of Juventas' claims and awarding CASI wasted costs, interest, tribunal costs, and legal fees totaling well over RMB 100 million. This provides a material cash infusion and removes a significant legal overhang for the clinical-stage biotech.
Key Facts
- Tribunal rejected all of Juventas' allegations that CASI breached the parties' agreements.
- Tribunal determined Juventas wrongfully terminated the commercialization agreements for CNCT-19.
- Award includes all wasted costs, interest from the date of wrongful termination, CASI's share of tribunal and HKIAC costs, and a substantial portion of legal costs.
- Total award is 'well over RMB 100 million' (approximately $14M+ USD).
Financial Impact
Well over RMB 100 million (approx. $14M+ USD) in cash award, including costs and interest.
Risk Factors
- Award may be subject to appeal or enforcement challenges in Hong Kong courts.
- Exact amount is not precisely quantified ('well over RMB 100 million').
- CNCT-19 commercialization rights remain unresolved despite the financial award.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (CASIF) — Batch item 1 | 0001104659-26-083702 |
| Document: 0001104659-26-083702-index-headers.html | 0001104659-26-083702 |
| Document: 0001104659-26-083702-index.html | 0001104659-26-083702 |
| Document: 0001104659-26-083702.txt | 0001104659-26-083702 |
| 6-K Filing (CASIF) — Batch item 5 | 0001104659-26-083702 |
| Document: 0001104659-26-083702-index-headers.html | 0001104659-26-083702 |
| Document: 0001104659-26-083702-index.html | 0001104659-26-083702 |
| Document: 0001104659-26-083702.txt | 0001104659-26-083702 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 2, 2026 7w ago | 6-K | $0.1400 | awaiting T+60 | — | $0.1000 (−28.57%) |
Aug 14, 2026 10w ago | 6-K | $0.1500 | awaiting T+60 | — | $0.1000 (+33.33%) |
Jul 15, 2026 14w ago | 6-K | $0.1400 $0.1100 | ▼ −21.43% | ▼ −24.22% | $0.1000 (−28.57%) |
Jun 29, 2026 17w ago | 6-K | $0.1200 $0.1300 | ▲ +8.33% | ▲ +5.29% | $0.1000 (−16.67%) |
Jun 2, 2026 21w ago | 6-K | $0.1100 $0.1300 | ▲ +18.18% | ▲ +17.06% | $0.1000 (−9.09%) |
Apr 23, 2026 26w ago | 3 | $0.1300 $0.1700 | ▲ +30.77% | ▲ +25.75% | $0.1000 (−23.08%) |
Apr 20, 2026 27w ago | 6-K | $0.1700 $0.1344 | ▼ −20.94% | ▼ −27.84% | $0.1000 (−41.18%) |
Apr 20, 2026 27w ago | 6-K | $0.1700 $0.1250 | ▲ +26.47% | ▲ +33.25% | $0.1000 (+41.18%) |
Apr 15, 2026 27w ago | 6-K | $0.1500 $0.1451 | ▼ −3.27% | ▼ −11.40% | $0.1000 (−33.33%) |
Apr 3, 2026 29w ago | 3 | $0.1400 $0.2400 | ▲ +71.43% | ▲ +57.96% | $0.1000 (−28.57%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers